Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14396MR)

This product GTTS-WQ14396MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14396MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8997MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMA-638
GTTS-WQ6430MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ1026MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
GTTS-WQ1181MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABP 501
GTTS-WQ12018MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ4347MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ14774MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ10137MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LAG-525
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW